<DOC>
	<DOCNO>NCT02301130</DOCNO>
	<brief_summary>Mogamulizumab Combination MEDI4736 Mogamulizumab Combination Tremelimumab Subjects Advanced Solid Tumors</brief_summary>
	<brief_title>Study Mogamulizumab + MEDI4736 Mogamulizumab + Tremelimumab Subjects w/ Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>Age â‰¥ 18 year ; Locally advance metastatic solid tumor ; Histologically cytologically confirm disease ; Failed intolerant least one prior systemic treatment regimen oral IV medication additional therapy option know prolong survival . Subjects nonsmall cell lung cancer must receive least one platinum doublet regimen . Subjects know epidermal growth factor receptor tyrosine kinase inhibitor activate mutation anaplastic lymphoma kinase rearrangement must also exhaust approve targeted therapy option ; Any concurrent chemotherapy , biologic , hormonal , radiation , investigative therapy cancer treatment within 21 day prior ; Concurrent prior use immunosuppressive medication within 28 day ; Active prior document autoimmune inflammatory bowel disease within 3 year exception ; Prior hypersensitivity reaction monoclonal antibody , therapeutic protein , immunotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>advanced solid tumor</keyword>
	<keyword>solid tumor</keyword>
	<keyword>mogamulizumab</keyword>
	<keyword>non-small cell lung</keyword>
	<keyword>pancreatic</keyword>
	<keyword>head neck</keyword>
</DOC>